Amgen Reports post-marketing Data for Lenacapavir in Psoriasis

Amgen today announced post-marketing results for lenacapavir in patients with psoriasis. The study demonstrated that lenacapavir reduces biomarker levels compared to standard of care or placebo. These results provide important insights into the treatment of psoriasis and support the continued development of lenacapavir in this patient population. The data were presented at a major medical conference and will be submitted for publication in a peer-reviewed journal. Regulatory submissions are planned based on these results.